(UroToday.com) As part of the “Game-changing Session 4” plenary session at the European Association of Urology (EAU) Virtual Annual Meeting, Dr. Bedke discussed health-related quality of life analysis from the KEYNOTE-426 trial. As most UroToday readers will know, the primary analysis of the KEYNOTE-426 trial demonstrated a significant survival advantage for patients with metastatic renal cell carcinoma who received pembrolizumab and axitinib as compared to those who received sunitinib.